GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea · Delayed Price · Currency is KRW 4,950.00
+80.00 (1.64%)
At close: Jul 31, 2026
GeneBioTech Co. ,Ltd Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 42,622 | 34,528 | 28,329 | 37,542 | 34,356 | 45,119 | |
Market Cap Growth | 14.72% | 21.88% | -24.54% | 9.27% | -23.86% | -8.87% |
Enterprise Value | 32,553 | 26,516 | 19,776 | 30,940 | 31,105 | 35,590 |
Last Close Price | 4950.00 | 4010.00 | 3249.43 | 4306.24 | 3940.80 | 5175.39 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.88 | 9.11 | 9.89 | 14.49 | 22.55 | - |
PS Ratio | 0.48 | 0.38 | 0.34 | 0.47 | 0.42 | 0.72 |
PB Ratio | 0.77 | 0.63 | 0.56 | 0.78 | 0.75 | 1.03 |
P/TBV Ratio | 0.78 | 0.64 | 0.56 | 0.79 | 0.77 | 1.05 |
P/FCF Ratio | 14.00 | 8.95 | - | 5.49 | - | - |
P/OCF Ratio | 6.76 | 4.54 | - | 5.10 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.36 | 0.29 | 0.24 | 0.39 | 0.38 | 0.57 |
EV/EBITDA Ratio | 6.04 | 4.93 | 3.79 | 5.83 | 10.94 | 44.98 |
EV/EBIT Ratio | 8.12 | 6.64 | 5.15 | 7.79 | 19.98 | - |
EV/FCF Ratio | 10.69 | 6.88 | - | 4.52 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.30 | 0.27 | 0.31 | 0.26 | 0.28 | 0.23 |
Debt / EBITDA Ratio | 3.05 | 2.78 | 3.05 | 2.35 | 4.58 | 13.02 |
Debt / FCF Ratio | 5.40 | 3.88 | - | 1.83 | - | - |
Net Debt / Equity Ratio | -0.18 | -0.18 | -0.15 | -0.20 | -0.07 | -0.17 |
Net Debt / EBITDA Ratio | -1.87 | -1.85 | -1.44 | -1.79 | -1.08 | -9.46 |
Net Debt / FCF Ratio | -3.31 | -2.58 | 4.81 | -1.39 | 0.63 | 1.29 |
Asset Turnover | 1.18 | 1.23 | 1.20 | 1.22 | 1.33 | 1.03 |
Inventory Turnover | 4.57 | 4.92 | 4.37 | 4.35 | 4.97 | 4.59 |
Quick Ratio | 2.13 | 2.39 | 2.02 | 2.33 | 1.91 | 1.99 |
Current Ratio | 3.02 | 3.48 | 3.04 | 3.40 | 2.91 | 2.98 |
Return on Equity (ROE) | 6.72% | 7.15% | 5.77% | 5.51% | 3.40% | -1.03% |
Return on Assets (ROA) | 3.29% | 3.38% | 3.48% | 3.82% | 1.56% | -0.46% |
Return on Invested Capital (ROIC) | 7.59% | 7.75% | 7.65% | 7.49% | 3.30% | -1.39% |
Return on Capital Employed (ROCE) | 6.70% | 6.70% | 7.20% | 7.70% | 3.20% | -1.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.42% | 10.97% | 10.11% | 6.90% | 4.43% | -1.07% |
FCF Yield | 7.14% | 11.17% | -5.52% | 18.21% | -14.07% | -12.89% |
Buyback Yield / Dilution | -0.23% | -0.07% | 0.07% | - | - | - |
Total Shareholder Return | 0.78% | -0.07% | 0.07% | - | - | - |